Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Protein synthesis inhibitor

DRUG CLASS:

Protein synthesis inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	moxetumomab pasudotox Sensitive: A1 - Approval moxetumomab pasudotox Sensitive : A1	moxetumomab pasudotox Sensitive: A1 - Approval moxetumomab pasudotox Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	recombinant Sensitive: A1 - Approval recombinant Sensitive : A1	recombinant Sensitive: A1 - Approval recombinant Sensitive : A1
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	recombinant Sensitive: A1 - Approval recombinant Sensitive : A1	recombinant Sensitive: A1 - Approval recombinant Sensitive : A1
CD22 positive	Lymphoma	CD22 positive	Lymphoma	moxetumomab pasudotox Sensitive: C2 – Inclusion Criteria moxetumomab pasudotox Sensitive : C2	moxetumomab pasudotox Sensitive: C2 – Inclusion Criteria moxetumomab pasudotox Sensitive : C2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	MT-5111 Sensitive: C3 – Early Trials MT-5111 Sensitive : C3	MT-5111 Sensitive: C3 – Early Trials MT-5111 Sensitive : C3
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	MT-5111 Sensitive: C3 – Early Trials MT-5111 Sensitive : C3	MT-5111 Sensitive: C3 – Early Trials MT-5111 Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3
IDH2 mutation	Glioma	IDH2 mutation	Glioma	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D
IDH1 mutation	Glioma	IDH1 mutation	Glioma	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D
CD38 expression	Multiple Myeloma	CD38 expression	Multiple Myeloma	MT-0169 Sensitive: D – Preclinical MT-0169 Sensitive : D	MT-0169 Sensitive: D – Preclinical MT-0169 Sensitive : D
HER-2 expression	Breast Cancer	HER-2 expression	Breast Cancer	MT-5111 Sensitive: D – Preclinical MT-5111 Sensitive : D	MT-5111 Sensitive: D – Preclinical MT-5111 Sensitive : D
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	MT-5111 Sensitive: D – Preclinical MT-5111 Sensitive : D	MT-5111 Sensitive: D – Preclinical MT-5111 Sensitive : D
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	NM-301 + LCB01-0371 Sensitive: D – Preclinical NM-301 + LCB01-0371 Sensitive : D	NM-301 + LCB01-0371 Sensitive: D – Preclinical NM-301 + LCB01-0371 Sensitive : D